Biomimetic device and foreign body reaction cooperate for efficient tumour cell capture in murine advanced ovarian cancer
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Identificadores![](/xmlui/themes/Mirage2//images/despl_identif.png)
Identificadores
URI: http://hdl.handle.net/20.500.11940/16458
PMID: 32764154
DOI: 10.1242/dmm.043653
ISSN: 1754-8403
Visualización o descarga de ficheros![](/xmlui/themes/Mirage2//images/despl_contenidos.png)
Visualización o descarga de ficheros
Fecha de publicación
2020Título de revista
Disease Models & Mechanisms
Tipo de contenido
Journal Article
DeCS
biomimética | animales | neoplasias ováricas | matriz extracelular | línea celular | microambiente tumoral | neoplasias peritoneales | humanos | factores de tiempo | ensayos antitumorales por modelo de xenoinjerto | ratones | migración de cuerpo extrañoMeSH
Foreign-Body Migration | Xenograft Model Antitumor Assays | Peritoneal Neoplasms | Cell Line | Biomimetics | Humans | Time Factors | Mice | Extracellular Matrix | Animals | Tumor Microenvironment | Ovarian NeoplasmsResumen
Metastasis is facilitated by the formation of pre-metastatic niches through the remodelling of the extracellular matrix (ECM) promoted by haematopoietic and stromal cells. The impact of these primed sites is pronounced for intraperitoneal metastases, where the cavity-exposed ECM supports the attachment of the disseminating tumour cells. Likewise, implantation of biomaterial scaffolds influences metastatic progression systemically through a foreign body reaction (FBR). In this study, we integrated the concept of creating an artificial niche to capture tumour cells actively disseminating in the peritoneal cavity with a therapeutic strategy modulating the interactions of metastatic cells with the ECM. The aim was to transform a disseminated disease into a focal disease. For this, we designed and developed a 'biomimetic' ECM composed of a nonresorbable three-dimensional scaffold with collagen coating and characterized the FBR to the implanted biomaterial. We also analysed the safety of the implanted devices and their ability to capture tumour cells in different murine preclinical models of advanced ovarian cancer. Implantation of the biomimetic devices resulted in an initial inflammatory reaction that transformed progressively into a fibrous connective tissue response. The adhesive capabilities of the scaffold were improved with the ancillary effect of the FBR and showed clinical utility in terms of the efficacy of capture of tumour cells, disease focalization and survival benefit. These results demonstrated the performance and safety of this 'biomimetic' ECM in preclinical models of advanced ovarian cancer. Translated into the clinical setting, this new therapeutic strategy represents the possibility for control of peritoneal carcinomatosis upon primary ovarian debulking surgery and to expand the percentage of patients who are candidates for second rescue surgeries at the time of relapse.
![](/xmlui/themes/Mirage2//images/final_lines.png)